|
1. Rööst M, Nilsson P. Sleep disorders—a public health problem. Potential risk factor in the development of type 2 diabetes, hypertension, dyslipidemia and premature aging. Lakartidningen. 2002 Jan 17;99(3):154-7.
2. Edwards BA, O’Driscoll DM, Ali A, Jordan AS, Trinder J, Malhotra A. Aging and sleep: physiology and pathophysiology. Semin Respir Crit Care Med. 2010 Oct;31(5):618-33.
3. Altemus M, Rao B, Dhabhar FS, Ding W, Granstein RD. Stress-induced changes in skin barrier function in healthy women. J Invest Dermatol. 2001 Aug;117(2):309-17.
4. Kobayashi S, Hayashi K, Koyama S, et al. Actigraphy for the assessment of sleep quality in pediatric atopic dermatitis patients. Arerugi. 2010 Jun;59(6):706-15.
5. Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007 Jun;18(2):82-91.
6. Choi EH, Brown BE, Crumrine D, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2005 Mar;124(3):587-95.
7. Kahan V, Andersen ML, Tomimori J, Tufik S. Can poor sleep affect skin integrity? Med Hypotheses. 2010 Dec;75(6):535-7.
8. Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest. 1995 May;95(5):2281-90.
9. Gupta MA, Gupta AK. Psychodermatology: an update. J Am Acad Dermatol. 1996 Jun;34(6):1030-46.
10. Tausk FA, Nousari H. Stress and the skin. Arch Dermatol. 2001 Jan;137(1):78-82.
11. Grice KA. Transepidermal water loss in pathologic skin. In: Jarrett A (ed.). The Physiology and Pathophysiology of the Skin. London: Academic Press; 1980:2147-55.
12. Rostenberg A Jr. The role of psychogenic factors in skin diseases. Arch Dermatol. 1960 Jan;81:81-6.
13. Weissman MM, Greenwald S, Niño-Murcia G, Dement WC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry. 1997 Jul;19(4):245-50.
14. Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep. 1997 Oct;20(10):865-70.
15. Grandner MA, Hale L, Moore M, Patel NP. Mortality associated with short sleep duration: The evidence, the possible mechanisms, and the future. Sleep Med Rev. 2010 Jun;14(3):191-203.
16. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep. 1983;6(2):102-7.
17. Lavie P, Herer P, Peled R, et al. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep. 1995 Apr;18(3):149-57.
18. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009 Aug;6(8):e1000132.
19. Monjan AA. Perspective on sleep and aging. Front Neurol. 2010 Sep 28;1:124.
20. Opp MR. Cytokines and sleep. Sleep Med Rev. 2005 Oct;9(5):355-64.
21. Kapsimalis F, Richardson G, Opp MR, Kryger M. Cytokines and normal sleep. Curr Opin Pulm Med. 2005 Nov;11(6):481-4.
22. Imeri L, Opp MR. How (and why) the immune system makes us sleep. Nat Rev Neurosci. 2009;10(3):199-210.
23. Everson CA, Toth LA. Systemic bacterial invasion induced by sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R905–16.
24. Gilliland MA, Bergmann BM, Rechtschaffen A. Sleep deprivation in the rat: VIII. High EEG amplitude sleep deprivation. Sleep. 1989 Feb 12;12(1):53–9.
25. Kushida CA, Everson CA, Suthipinittharm P, et al. Sleep deprivation in the rat: VI. Skin changes. Sleep. 1989 Feb;12(1):42–6.
26. Rechtschaffen A, Bergmann BM. Sleep deprivation in the rat by the disk-over- water method. Behav Brain Res. 1995 Jul-Aug;69(1-2):55–63.
27. Shukla R, Sasseville D. Psychopharmacology in psychodermatology. J Cutan Med Surg. 2008 Nov-Dec;12(6):255-67.
28. Buljan D, Buljan M, Situm M. Psychodermatology: a brief review for clinicians. Psychiatr Danub. 2005 Jun;17(1-2):76-83.
29. Koo J, Lebwohl A. Psycho dermatology: the mind and skin connection. Am Fam Physician. 2001 Dec 1;64(11):1873-8.
30. Roupe G. Skin of the aging human being. Lakartidningen. 2001 Mar;98(10):1091–5.
31. Plat L, Leproult R, L’Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999 Sep;84(9):3082-92.
32. Chanvorachote P, Pongrakhananon V, Luanpitpong S, Chanvorachote B, Wannachaiyasit S, Nimmannit U. Type I pro-collagen promoting and anti-collagenase activities of Phyllanthus emblica extract in mouse fibroblasts. J Cosmet Sci. 2009;60(4):395-403.
33. Datta HS, Mitra SK, Patwardhan B. Wound healing activity of topical application forms based on Ayurveda. Evid Based Complement Alternat Med. 2009 Feb 27.
34. Fujii T, Wakaizumi M, Ikami T, Saito M. Amla (Emblica officinalis Gaertn.) extract promotes procollagen production and inhibits matrix metalloproteinase-1 in human skin fibroblasts. J Ethnopharmacol. 2008;119(1):53-7.
35. Prakash J, Gupta SK, Dinda AK. Withania somnifera root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. Nutr Cancer. 2002;42(1):91-7.
36. Chaudhuri RK. Emblica cascading antioxidant: a novel natural skin care ingredient. Skin Pharmacol Appl Skin Physiol. 2002;15(5):374-80.
37. Kumar MS, Kirubanandan S, Sripriya R, Sehgal PK. Triphala promotes healing of infected full-thickness dermal wound. J Surg Res. 2008;144(1):94-101.
38. Sancheti G, Jindal A, Kumari R, Goyal PK. Chemopreventive action of emblica officinalis on skin carcinogenesis in mice. Asian Pac J Cancer Prev. 2005;6(2):197-201.
39. Ngamkitidechakul C, Jaijoy K, Hansakul P, Soonthornchareonnon N, Sireeratawong S. Antitumour effects of Phyllanthus emblica L.: induction of cancer cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells. Phytother Res. 2010;24(9):1405-13.
40. Adil MD, Kaiser P, Satti NK, Zargar AM, Vishwakarma RA, Tasduq SA. Effect of Emblica officinalis (fruit) against UVB-induced photo-aging in human skin fibroblasts. J Ethnopharmacol. 2010 Oct 28;132(1):109-14.
41. Abedon B. Sensara White Paper. NutraGenesis LLC. 2009.
42. Biswajit A, Hazra J, Mitra A, Abedon B, Ghosal S. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: A double-blind, randomized, placebo-controlled study. JANA. 2008;11(1):50-6.
43. Brzezinski A. Melatonin in humans. N Engl J Med. 1997 Jan 16;336(3):186-95.
44. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003 Apr;15(4):432-7.
45. Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep. 2006 May 1;29(5):609-18.
46. Gorfine T, Assaf Y, Goshen-Gottstein Y, Yeshurun Y, Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006 May 15;31(1):410-18.
47. Gorfine T, Zisapel N. Melatonin and the human hippocampus: a time dependent interplay. J Pineal Res. 2007 Aug;43(1):80-6.
48. Lynch HJ, Ozaki Y, Shakal D, Wurtman RJ: Melatonin excretion of man and rats: effect of time of day, sleep, pinealectomy and food consumption. Int J Biometeorol. 1975 Dec;19(4):267-79.
49. Sharma M, Palacios-Bois J, Iskandar H, Thakur M, Quirion R, Nair NPV. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry. 1989 Feb 1;25:305-19.
50. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ. 1994 Jul 16;309(6948):167.
51. Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res. 1994 Jul 18;651(1-2):134-42.
52. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004 Jan 15;116(2):91-5.
53. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995 Aug 26;346(8974):541-4.
54. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995 Sep;18(7):598-603.
55. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007 Dec;16(4):372-80.
56. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007 Oct; 23(10):2597-605.
57. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009 Sep;24(5):239-49.
58. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010 Aug 16;8:51. |